Journal article

Sofosbuvir and Ribavirin for 6 Weeks Is Not Effective Among People With Recent Hepatitis C Virus Infection: The DARE-C II Study

Marianne Martinello, Edward Gane, Margaret Hellard, Joe Sasadeusz, David Shaw, Kathy Petoumenos, Tanya Applegate, Jason Grebely, Laurence Maire, Philippa Marks, Gregory J Dore, Gail V Matthews

HEPATOLOGY | WILEY | Published : 2016

Abstract

While interferon-based therapy has excellent efficacy in acute and recent hepatitis C virus (HCV) infection, the side effect profile limits implementation. Sofosbuvir and ribavirin for 12-24 weeks is safe and well tolerated in chronic HCV, with efficacy dependent on genotype and disease stage. The aim of this study was to assess the efficacy of sofosbuvir and ribavirin for 6 weeks in individuals with recent HCV infection. In this open-label study conducted in Australia and New Zealand, adults with recent HCV (duration of infection <12 months) received sofosbuvir 400 mg daily and weight-based ribavirin (<75 kg, 1,000 mg/day; ≥75 kg, 1,200 mg/day) for 6 weeks. The primary efficacy endpoint was..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian government. The Burnet Institute receives funding from the Victorian Operational Infrastructure Support Program. Research reported in this publication was supported by Gilead Sciences Inc. as an investigator-initiated study. The content is solely the responsibility of the authors. Jason Grebely and Gail Matthews are Supported by the National Health and Medical Research Council (Career Development Fellowships to J.G. and G.V.M., Practitioner Fellowships to G.J.D., and a Principal Research Fellowship to M.H.).